Dianthus Therapeutics completes patient enrollment in phase 2 MaGic trial of DNTH103 in generalized myasthenia gravis
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, announced completion of enrollment in the phase 2 MaGic trial of DNTH103 …